{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:56:12Z","timestamp":1793386572268,"version":"4.5.0"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalnutritionespen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition ESPEN"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clnesp.2025.10.031","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T03:33:53Z","timestamp":1762313633000},"page":"591-603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Decreased appetite in cancer patients treated with immune checkpoint inhibitors (ICIs): The MOUSEION-012 systematic review and meta-analysis"],"prefix":"10.1016","volume":"70","author":[{"given":"Elsa","family":"Vitale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Maistrello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Cauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Mollica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Sabino","family":"Marques Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Massari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clnesp.2025.10.031_bib1","first-page":"73","article-title":"Cancer in the elderly","volume":"2","author":"Cinar","year":"2015","journal-title":"North Clin Istanb"},{"issue":"1","key":"10.1016\/j.clnesp.2025.10.031_bib2","first-page":"47","article-title":"Comparison of a novel, simple nutrition screening tool for adult oncology inpatients and the Malnutrition Screening Tool (MST) against the patient-generated subjective global assessment (PG-SGA)","volume":"23","author":"Shaw","year":"2015","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.clnesp.2025.10.031_bib3","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.clnu.2021.02.005","article-title":"ESPEN practical guideline: Clinical nutrition in cancer","volume":"40","author":"Muscaritoli","year":"2021","journal-title":"Clin Nutr"},{"issue":"11","key":"10.1016\/j.clnesp.2025.10.031_bib4","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.2174\/1871530321666210114154401","article-title":"The role of nutrition during the COVID-19 pandemic: what we know","volume":"21","author":"Vitale","year":"2021","journal-title":"Endocr, Metab Immune Disord: Drug Targets"},{"issue":"1","key":"10.1016\/j.clnesp.2025.10.031_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.archger.2013.08.006","article-title":"Orthopedic multidimensional prognostic index (Ortho-MPI) in the elderly with hip or neck femur fracture: a pilot study","volume":"58","author":"Vitale","year":"2014","journal-title":"Arch Gerontol Geriatr"},{"issue":"5","key":"10.1016\/j.clnesp.2025.10.031_bib6","first-page":"2393","article-title":"Probiotics as adjuvant therapy in the treatment of allergic rhinitis","volume":"16","author":"Mancin","year":"2023","journal-title":"Res J Pharm Technol"},{"key":"10.1016\/j.clnesp.2025.10.031_bib7","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.clnesp.2023.10.033","article-title":"Nutritional prehabilitation in head and neck cancer: a systematic review of literature","volume":"58","author":"De Pasquale","year":"2023","journal-title":"Clin Nutr ESPEN"},{"issue":"8","key":"10.1016\/j.clnesp.2025.10.031_bib8","doi-asserted-by":"crossref","first-page":"555","DOI":"10.21037\/atm.2020.01.87","article-title":"Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition","volume":"8","author":"de Silva","year":"2020","journal-title":"Ann Transl Med"},{"issue":"9","key":"10.1016\/j.clnesp.2025.10.031_bib9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.clnesp.2025.10.031_bib10","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1634\/theoncologist.2015-0507","article-title":"FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy","volume":"21","author":"Kazandjian","year":"2016","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.clnesp.2025.10.031_bib11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3390\/ph15030335","article-title":"Revolutionization in cancer therapeutics via targeting major immune Checkpoints PD-1, PD-L1 and CTLA-4","volume":"15","author":"Pandey","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"4","key":"10.1016\/j.clnesp.2025.10.031_bib12","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.clinthera.2015.02.018","article-title":"The next immune-checkpoint inhibitors: PD-1\/PD-L1 blockade in Melanoma","volume":"37","author":"Mahoney","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.clnesp.2025.10.031_bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fonc.2020.00091","article-title":"Potential immune-related adverse events associated with monotherapy and combination therapy of Ipilimumab, nivolumab, and Pembrolizumab for advanced melanoma: a systematic review and meta-analysis","volume":"10","author":"Almutairi","year":"2020","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.clnesp.2025.10.031_bib14","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/cpt.633","article-title":"Meta-analysis of the risk of immune-related adverse events with anticytotoxic T-Lymphocyte-Associated antigen 4 and antiprogrammed death 1 therapies","volume":"103","author":"Komaki","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"1549","key":"10.1016\/j.clnesp.2025.10.031_bib15","first-page":"11","article-title":"Nutrition support in oncology care in Aotearoa New Zealand: current practice, and where to from here?","volume":"135","author":"Peniamina","year":"2022","journal-title":"N Z Med J"},{"issue":"5","key":"10.1016\/j.clnesp.2025.10.031_bib16","first-page":"2435","article-title":"The provision of nutritional advice and care for cancer patients: a UK national survey of healthcare professionals","volume":"29","author":"Murphy","year":"2021","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clnesp.2025.10.031_bib17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"7414","key":"10.1016\/j.clnesp.2025.10.031_bib18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.clnesp.2025.10.031_bib19","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/jrsm.1348","article-title":"Seriously misleading results using inverse of freeman-Tukey double arcsine transformation in meta-analysis of single proportions","volume":"10","author":"Schwarzer","year":"2019","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.clnesp.2025.10.031_bib20","series-title":"Practical meta-analysis","author":"Lipsey","year":"2001"},{"issue":"29","key":"10.1016\/j.clnesp.2025.10.031_bib21","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1002\/sim.4040","article-title":"Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data","volume":"29","author":"Stijnen","year":"2010","journal-title":"Stat Med"},{"key":"10.1016\/j.clnesp.2025.10.031_bib22","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1002\/sim.8158","article-title":"Network meta-analysis of rare events using the Mantel-Haenszel method","volume":"38","author":"Efthimiou","year":"2019","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.clnesp.2025.10.031_bib23","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"issue":"17","key":"10.1016\/j.clnesp.2025.10.031_bib26","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/sim.1482","article-title":"Improved tests for a random effects meta-regression with a single covariate","volume":"22","author":"Knapp","year":"2003","journal-title":"Stat Med"},{"issue":"7300","key":"10.1016\/j.clnesp.2025.10.031_bib27","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1136\/bmj.322.7300.1479","article-title":"Forest plots: trying to see the wood and the trees","volume":"322","author":"Lewis","year":"2001","journal-title":"BMJ"},{"issue":"7121","key":"10.1016\/j.clnesp.2025.10.031_bib28","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1136\/bmj.315.7121.1533","article-title":"Meta-analysis: principles and procedures","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"22","key":"10.1016\/j.clnesp.2025.10.031_bib29","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clnesp.2025.10.031_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100270","article-title":"Trifluridine\/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study","volume":"6","author":"Bordonaro","year":"2021","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.clnesp.2025.10.031_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000453","article-title":"Phase IA\/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors","volume":"8","author":"Desai","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"22","key":"10.1016\/j.clnesp.2025.10.031_bib32","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1002\/cncr.33133","article-title":"First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors","volume":"126","author":"Geva","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.clnesp.2025.10.031_bib33","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.clnesp.2021.12.024","article-title":"A historic cohort study of nutritional status related side effects and weight loss of cancer patients treated with immunotherapy","volume":"47","author":"Homan","year":"2022","journal-title":"Clin Nutr ESPEN"},{"issue":"1","key":"10.1016\/j.clnesp.2025.10.031_bib34","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jval.2024.09.009","article-title":"Most common symptomatic adverse reactions of cancer treatments from US drug labels (2015-2021) to inform selection of patient-reported outcomes","volume":"28","author":"Horodniceanu","year":"2025","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.clnesp.2025.10.031_bib35","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00432-018-02835-6","article-title":"ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study","volume":"145","author":"Iivanainen","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.clnesp.2025.10.031_bib36","article-title":"Decisional conflict and its determinants among patients with cancer undergoing immunotherapy combined with chemotherapy or targeted therapy: a cross-sectional study","volume":"13","author":"Lee","year":"2023","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.clnesp.2025.10.031_bib37","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/cei\/uxad105","article-title":"Toxicity spectrum and risk factors for chemo-immunotherapy in locally advanced or metastatic lung cancer","volume":"214","author":"Li","year":"2023","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.clnesp.2025.10.031_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010035","article-title":"Safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria","volume":"13","author":"Li","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.clnesp.2025.10.031_bib39","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1007\/s11136-023-03460-8","article-title":"Associations between treatments, comorbidities and multidimensional aspects of quality of life among patients with advanced cancer in the Netherlands-a 2017-2020 multicentre cross-sectional study","volume":"32","author":"Malhotra","year":"2023","journal-title":"Qual Life Res"},{"issue":"10","key":"10.1016\/j.clnesp.2025.10.031_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003288","article-title":"JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma","volume":"9","author":"Miyamoto","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.clnesp.2025.10.031_bib41","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1634\/theoncologist.2017-0087","article-title":"FDA approval summary: atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum-containing chemotherapy","volume":"22","author":"Ning","year":"2017","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.clnesp.2025.10.031_bib42","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2159-8290.CD-18-0229","article-title":"Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations","volume":"8","author":"Pal","year":"2018","journal-title":"Cancer Discov"},{"issue":"Pt B","key":"10.1016\/j.clnesp.2025.10.031_bib43","article-title":"Neoadjuvant chemoimmunotherapy for laryngeal preservation in locally advanced hypopharyngeal cancer","volume":"142","author":"Pan","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"10.1016\/j.clnesp.2025.10.031_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35738","article-title":"Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer","volume":"131","author":"Sands","year":"2025","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.clnesp.2025.10.031_bib45","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1200\/JCO.23.01462","article-title":"Patient-Reported outcomes from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"42","author":"Sangro","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clnesp.2025.10.031_bib46","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s12885-018-4234-8","article-title":"A phase I\/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer","volume":"18","author":"Sundar","year":"2018","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.clnesp.2025.10.031_bib47","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/CMR.0000000000000744","article-title":"Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study","volume":"31","author":"Tacar","year":"2021","journal-title":"Melanoma Res"},{"issue":"7","key":"10.1016\/j.clnesp.2025.10.031_bib48","doi-asserted-by":"crossref","first-page":"7772","DOI":"10.1002\/cam4.5535","article-title":"Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab","volume":"12","author":"Tada","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.clnesp.2025.10.031_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1282629","article-title":"Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real-world retrospective study","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.clnesp.2025.10.031_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijnurstu.2022.104430","article-title":"Unpleasant symptoms of immunotherapy for people with lung cancer: a mixed-method study","volume":"139","author":"Zhang","year":"2023","journal-title":"Int J Nurs Stud"},{"issue":"3","key":"10.1016\/j.clnesp.2025.10.031_bib51","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1179\/1607845414Y.0000000179","article-title":"Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma","volume":"20","author":"Zhou","year":"2015","journal-title":"Hematology"},{"issue":"20","key":"10.1016\/j.clnesp.2025.10.031_bib52","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clnesp.2025.10.031_bib53","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S1470-2045(18)30673-9","article-title":"Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study","volume":"19","author":"Barlesi","year":"2018","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.clnesp.2025.10.031_bib54","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clnesp.2025.10.031_bib55","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clnesp.2025.10.031_bib56","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clnesp.2025.10.031_bib57","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"10030","key":"10.1016\/j.clnesp.2025.10.031_bib58","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.clnesp.2025.10.031_bib59","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"issue":"10027","key":"10.1016\/j.clnesp.2025.10.031_bib60","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.clnesp.2025.10.031_bib61","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-Selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"issue":"10183","key":"10.1016\/j.clnesp.2025.10.031_bib62","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.clnesp.2025.10.031_bib63","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clnesp.2025.10.031_bib64","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clnesp.2025.10.031_bib65","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3390\/biology13050352","article-title":"Associations between \u201cCancer Risk\u201d, \u201cInflammation\u201d and \u201cMetabolic Syndrome\u201d: a scoping review","volume":"13","author":"Vitale","year":"2024","journal-title":"Biology"},{"issue":"11","key":"10.1016\/j.clnesp.2025.10.031_bib66","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3390\/cancers16111969","article-title":"Sex differences in anxiety and depression conditions among cancer patients: a systematic review and meta-analysis","volume":"16","author":"Vitale","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.clnesp.2025.10.031_bib67","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1186\/s12885-024-12289-4","article-title":"An evaluation of nutritional impact symptoms and their association with reduced dietary intake in patients with solid tumors at tertiary care hospitals: a multicenter, cross-sectional study from Palestine","volume":"24","author":"Shakhshir","year":"2024","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.clnesp.2025.10.031_bib68","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/SPC.0000000000000669","article-title":"Loss of appetite in patients with cancer: an update on characterization, mechanisms, and palliative therapeutics","volume":"17","author":"Haemmerle","year":"2023","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.clnesp.2025.10.031_bib69","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221148921","article-title":"Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial","volume":"15","author":"Tibau","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"10.1016\/j.clnesp.2025.10.031_bib70","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch","year":"2012","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.clnesp.2025.10.031_bib71","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1038\/s41467-022-32135-0","article-title":"Blocking ActRIIB and restoring appetite reverses cachexia and improves survival in mice with lung cancer","volume":"13","author":"Queiroz","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.clnesp.2025.10.031_bib72","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbrc.2022.08.011","article-title":"Atractylodin alleviates cancer anorexia-cachexia syndrome by regulating NPY through hypothalamic Sirt1\/AMPK axis-induced autophagy","volume":"625","author":"Yu","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clnesp.2025.10.031_bib73","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bbi.2022.11.008","article-title":"The GDF15-GFRAL axis mediates chemotherapy-induced fatigue in mice","volume":"108","author":"Chelette","year":"2023","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.clnesp.2025.10.031_bib74","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","article-title":"Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape","volume":"81","author":"Emens","year":"2017","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.clnesp.2025.10.031_bib75","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41424-018-0049-9","article-title":"Immune checkpoint inhibitor-associated colitis and hepatitis","volume":"9","author":"Reddy","year":"2018","journal-title":"Clin Transl Gastroenterol"},{"issue":"21","key":"10.1016\/j.clnesp.2025.10.031_bib76","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clnesp.2025.10.031_bib77","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/jnci\/djad079","article-title":"The pathways to prevention program: nutrition as prevention for improved cancer outcomes","volume":"115","author":"Hiatt","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.clnesp.2025.10.031_bib78","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1200\/JOP.2016.016832","article-title":"Cancer cachexia: beyond weight loss","volume":"12","author":"Bruggeman","year":"2016","journal-title":"J Oncol Pract"},{"issue":"2","key":"10.1016\/j.clnesp.2025.10.031_bib79","first-page":"365","article-title":"Weight loss versus muscle loss: re-evaluating inclusion criteria for future cancer cachexia interventional trials","volume":"25","author":"Roeland","year":"2017","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.clnesp.2025.10.031_bib80","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10585-024-10327-w","article-title":"Metastatic sites and clinical outcomes in renal cell carcinoma patients receiving immune-based combinations: the MOUSEION-08 study","volume":"42","author":"Rizzo","year":"2024","journal-title":"Clin Exp Metastasis"},{"issue":"1","key":"10.1016\/j.clnesp.2025.10.031_bib81","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-71746-z","article-title":"Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis","volume":"14","author":"Vitale","year":"2024","journal-title":"Sci Rep"},{"issue":"17","key":"10.1016\/j.clnesp.2025.10.031_bib82","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.3390\/cancers14174142","article-title":"Adjuvant PD-1 and PD-L1 inhibitors and relapse-free survival in cancer patients: the MOUSEION-04 study","volume":"14","author":"Rizzo","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.clnesp.2025.10.031_bib83","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10585-024-10322-1","article-title":"Impact of time-of-day administration of immunotherapy on survival in metastatic renal cell carcinoma: the MOUSEION-09 meta-analysis","volume":"42","author":"Rizzo","year":"2024","journal-title":"Clin Exp Metastasis"},{"issue":"7","key":"10.1016\/j.clnesp.2025.10.031_bib84","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1136\/gutjnl-2024-333812","article-title":"British society of gastroenterology practice guidance on the management of acute and chronic gastrointestinal symptoms and complications as a result of treatment for cancer","volume":"74","author":"Andreyev","year":"2025","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.clnesp.2025.10.031_bib85","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/nu14020356","article-title":"When eating becomes torturous: understanding nutrition-related cancer treatment side effects among individuals with cancer and their caregivers","volume":"14","author":"Milliron","year":"2022","journal-title":"Nutrients"},{"issue":"10","key":"10.1016\/j.clnesp.2025.10.031_bib86","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.3390\/curroncol31100452","article-title":"Appetite loss in patients with advanced cancer treated at an acute palliative care unit","volume":"31","author":"Helgesen","year":"2024","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.clnesp.2025.10.031_bib87","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/1759-7714.12910","article-title":"Updates on the pathogenesis of advanced lung cancer-induced cachexia","volume":"10","author":"Zhu","year":"2019","journal-title":"Thorac Cancer"},{"issue":"1","key":"10.1016\/j.clnesp.2025.10.031_bib88","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/jcsm.12156","article-title":"Cancer anorexia: hypothalamic activity and its association with inflammation and appetite-regulating peptides in lung cancer","volume":"8","author":"Molfino","year":"2017","journal-title":"J Cachexia Sarcopenia Musc"},{"issue":"1","key":"10.1016\/j.clnesp.2025.10.031_bib89","article-title":"Gastrointestinal adverse events of immunotherapy","volume":"3","author":"Cappello","year":"2021","journal-title":"BJR Open"},{"issue":"1","key":"10.1016\/j.clnesp.2025.10.031_bib90","doi-asserted-by":"crossref","DOI":"10.4110\/in.2020.20.e9","article-title":"Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors","volume":"20","author":"Choi","year":"2020","journal-title":"Immune Netw"},{"issue":"17","key":"10.1016\/j.clnesp.2025.10.031_bib91","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"National comprehensive cancer network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clnesp.2025.10.031_bib92","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/gastro\/goz065","article-title":"Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy","volume":"8","author":"Rajha","year":"2019","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"4","key":"10.1016\/j.clnesp.2025.10.031_bib93","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clnesp.2025.10.031_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103826","volume":"180","author":"Faggiano","year":"2022","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Clinical Nutrition ESPEN"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457725029894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457725029894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T08:43:47Z","timestamp":1764405827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405457725029894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":92,"alternative-id":["S2405457725029894"],"URL":"https:\/\/doi.org\/10.1016\/j.clnesp.2025.10.031","relation":{},"ISSN":["2405-4577"],"issn-type":[{"value":"2405-4577","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decreased appetite in cancer patients treated with immune checkpoint inhibitors (ICIs): The MOUSEION-012 systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition ESPEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnesp.2025.10.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}